Skip to content

Cara Therapeutics continuing Phase 3 post-op pain med trial

June 22, 2017

Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment

* Cara Therapeutics – ‍based on guidance of idmc, trial will continue to test 2 doses of cr845 versus placebo in up to 450 patients undergoing abdominal surgery​

* Cara Therapeutics Inc – trial will continue to test two doses of cr845 and aims to enroll up to 450 patients

* Cara Therapeutics Inc – both doses of cr845 well tolerated

* Cara Therapeutics Inc – trial completion expected in q4 of 2017 for cr845

http://reut.rs/2sDIhlS

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: